Day: March 15, 2022

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BOSTON, March 15, 2022 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...

Fiscal Year 2021 Net Sales and Adjusted EBITDA Exceeds Full-Year GuidanceFourth Quarter Net Sales +17% on Continued Strong Consumption and Accelerating Share GainsProvides Fiscal Year 2022 Guidance LOUISVILLE, Colo., March 15, 2022 (GLOBE NEWSWIRE) — Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO), the fastest-growing food company of scale in the United States, today reported financial results for its fourth quarter and fiscal year ended December 25, 2021. Fourth Quarter Highlights:Net sales were $189.2 million, a 17.0% increase over the prior year period, led by strong volume growth across core categories – sauce, yogurt and frozen Rao’s became the #2 pasta and pizza sauce brand, with dollar market share reaching an all-time high of 15.4%; household penetration for Rao’s sauce also reached a new record of...

Record Q1 net revenue of $7.0 million, up from $6.6 million in Q1 2021 Volume growth of 22% as a result of stronger velocities and increased points of sale Fastest growing energy drink in Canada in the last 52 weeks1 Gross margin of 55% (versus 51% in Q4 2021 and 62% in Q1 2021), reflecting the change in the Company’s business model for the Canadian market since Q4 2021 Strong financial position with cash and unused credit facilities of over $70 million to support ongoing North American growth plans Subsequent to Q1, GURU increased its points of sale by 1,500 retail locations, primarily in California, supported by an expanded DSD distributor network Subsequent to Q1, launch of GURU Guayusa Tropical Punch across Canada following successful launch in Quebec, where Guayusa ranks as the #6 Top SKU in C&G2. The launch will be supported...

– Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients – – Presented positive initial dose-escalation clinical data for SL-279252, including anti-tumor activity, high target occupancy, and dose-dependent immune activation in heavily pretreated cancer patients – AUSTIN, TX and DURHAM, NC, March 15, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business...

APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for April 8, 2022 Ended 2021 with $219.7 million in cash, sufficient to fund operations into 2024 CAMBRIDGE, Mass. and BOULDER, Colo., March 15, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. “In 2021, Cogent achieved substantial progress toward our goal of establishing bezuclastinib as a best-in-class KIT mutant inhibitor for systemic mastocytosis and gastrointestinal stromal tumor (GIST) patients,” said Andrew Robbins, President and CEO...

2021 revenue of $91.5 million, net income of $23 millionYear-end cash and equivalents of $129 millionExplosive growth in self-balancing scooter segment, up over 400%JINHUA, CHINA, March 15, 2022 (GLOBE NEWSWIRE) —  Kandi Technologies Group, Inc. (the “Company,” “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the full year ended December 31, 2021. Full Year 2021 Highlights • Total revenue was $91.5 million, compared to $76.9 million in 2020. • EV parts sales were $25.3million, compared to $40.6 million in 2020. • Off-road vehicles sales were $29.3 million, compared to $29.8 million in 2020. • EV product sales increased by 116% to $1.5 million, compared to $0.7 million in 2020. • Electric Scooters, Electric Self-Balancing Scooters and associated parts sales increased by 420.6% to $30.0 million,...

PLANO, Texas, March 15, 2022 (GLOBE NEWSWIRE) — Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT), an e-commerce-focused financial technology company, today reported its financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter and Full Year 2021 Financial and Operational Highlights:Recorded total revenue of $73.3 million in fourth quarter 2021 which was flat compared to prior year. Revenue for full year 2021 was $303.1 million as compared to $247.2 million in prior year, an increase of 23%.Added 20 new merchants in the fourth quarter 2021, despite ongoing macro challenges bringing our total to 102 new merchants for 2021, up 127% from a total of 45 new merchants in 2020.Achieved continued high customer satisfaction with Net Promoter Score of 54 as of December 31, 2021 and...

Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million, Representing a 20% to 30% Increase over 2021; 2022 EBITDA Margins Anticipated Between 12%–15%, Representing More Than 2.5X over 2021 EBITDA. Integration of Newly Acquired Portfolio of Four FDA-Approved Commercial Products is Progressing as Planned with Expanded Sales in International Markets. Advancing the Plan for the Opening of New U.S. Plasma Collection Centers. Company Expands U.S. Leadership Team with Multiple Key Hires to Drive Sales of Proprietary Products and Expansion of Plasma Collection Operations. Added Two New Biosimilar Product Candidates in Israel; Increasing the Expected Potential Collective Annual Peak Sales of the Entire...